Contact Us
Home Jazz Pharmaceuticals, Inc. to Announce Second Quarter 2007 Financial Results on August 9, 2007

News Release

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Jazz Pharmaceuticals, Inc. to Announce Second Quarter 2007 Financial Results on August 9, 2007

July 26, 2007
PDF Version
PALO ALTO, Calif., July 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its second quarter 2007 financial results on Thursday, August 9, 2007 following the close of the U.S. financial markets. Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss the quarterly results and company updates on August 9, 2007 at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The live webcast and press release may be accessed on Jazz Pharmaceuticals' website at http://www.jazzpharmaceuticals.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. An archived version of the webcast will be available through August 23, 2007.

Investors may participate in the conference call by dialing 1-800-299-0433 in the U.S., or 1-617-801-9712 outside the U.S., and entering passcode 23108551. A replay of this call will be available until August 23, 2007 at 1-888-286-8010 (U.S.), or 1-617-801-6888 (international), using the passcode 26350949.

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at http://www.fulldisclosure.com and institutional investors can access the call via http://www.streetevents.com.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.

SOURCE Jazz Pharmaceuticals, Inc.

Jim Karrels, Senior Director of Finance of Jazz Pharmaceuticals, Inc., +1-650-496-2800, investorinfo@jazzpharma.com; Karen L. Bergman, +1-650-575-1509, Michelle Corral, +1-415-794-8662, both of BCC Partners, for Jazz Pharmaceuticals, Inc.

http://www.jazzpharmaceuticals.com